What the FDA labels say about taking them together
Aspirin, butalbital, caffeine and codeine and glimepiride
Aspirin, butalbital, caffeine and codeine's FDA label of May 27, 2026 names glimepiride in its drug interactions section; glimepiride's label does not name aspirin, butalbital, caffeine and codeine itself but warns about its class (Barbiturates, Stimulants, NSAIDs (nonsteroidal anti-inflammatory drugs), Opioids (opioid agonists), platelet aggregation inhibitors). The aspirin, butalbital, caffeine and codeine label: “Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia.”
Check it at the source: the aspirin, butalbital, caffeine and codeine FDA label on DailyMed (effective May 27, 2026, Bryant Ranch Prepack); the glimepiride FDA label on DailyMed (effective May 12, 2025, Micro Labs Limited).
What does the aspirin, butalbital, caffeine and codeine label say about glimepiride?
Aspirin, butalbital, caffeine and codeine label, drug interactionsClinical Impact: Aspirin may increase the serum glucose-lowering action of insulin and sulfonylureas leading to hypoglycemia. Intervention: Patients should be advised to consult a physician if any signs or symptoms of hypoglycemia occur. Insulin, glimepiride, glipizide Anticonvulsants
Source: FDA drug label (BUTALBITAL, ASPIRIN, CAFFEINE AND CODEINE PHOSPHATE), ANDA075231 (Lgm Pharma), as published by Bryant Ranch Prepack, effective May 27, 2026 (SPL set 95a33c9b-79a6-47c7-8433-fc217950b88f), via openFDA; the full label on DailyMed
What does the glimepiride label say about aspirin, butalbital, caffeine and codeine?
Glimepiride's label does not name aspirin, butalbital, caffeine and codeine itself; it warns about its class (Barbiturates, Stimulants, NSAIDs (nonsteroidal anti-inflammatory drugs), Opioids (opioid agonists), platelet aggregation inhibitors):
Glimepiride label, drug interactionsThe following are examples of medications that may increase the glucose-lowering effect of sulfonylureas including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines …
Glimepiride label, drug interactionsThe following are examples of medications that may reduce the glucose-lowering effect of sulfonylureas including glimepiride, leading to worsening glycemic control: danazol, glucagon, somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine …
Source: FDA drug label (Glimepiride), Micro Labs Limited, effective May 12, 2025 (SPL set 60e9397e-83b9-489e-9683-6f87e458bbaa), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aspirin, butalbital, caffeine and codeine | Glimepiride | |
|---|---|---|
| Labeled for | Pain | Type 2 diabetes |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $1.00 per capsule Ascomp with codeine capsule | $0.0507 per tablet 4 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once